A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Poly ICLC (Primary) ; Temozolomide
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 18 Jul 2017 Planned End Date changed from 30 Jun 2019 to 31 Oct 2019.
- 18 Jul 2017 Planned primary completion date changed from 31 Aug 2017 to 31 Dec 2017.
- 16 Feb 2017 Phase has been changed from phase 0 to phase 1.